Rehabilitation Decreases Spasticity by Restoring Chloride Homeostasis Through the Brain-Derived Neurotrophic Factor-KCC2 Pathway After Spinal Cord Injury
Overview
Neurology
Affiliations
Activity-based therapy is routinely integrated in rehabilitation programs to facilitate functional recovery after spinal cord injury (SCI). Among its beneficial effects is a reduction of hyperreflexia and spasticity, which affects ∼75% of the SCI population. Unlike current anti-spastic pharmacological treatments, rehabilitation attenuates spastic symptoms without causing an active depression in spinal excitability, thus avoiding further interference with motor recovery. Understanding how activity-based therapies contribute to decrease spasticity is critical to identifying new pharmacological targets and to optimize rehabilitation programs. It was recently demonstrated that a decrease in the expression of KCC2, a neuronal Cl extruder, contributes to the development spasticity in SCI rats. Although exercise can decrease spinal hyperexcitability and increase KCC2 expression on lumbar motoneurons after SCI, a causal effect remains to be established. Activity-dependent processes include an increase in brain-derived neurotrophic factor (BDNF) expression. Interestingly, BDNF is a regulator of KCC2 but also a potent modulator of spinal excitability. Therefore, we hypothesized that after SCI, the activity-dependent increase in KCC2 expression: 1) functionally contributes to reduce hyperreflexia, and 2) is regulated by BDNF. SCI rats chronically received VU0240551 (KCC2 blocker) or TrkB-IgG (BDNF scavenger) during the daily rehabilitation sessions and the frequency-dependent depression of the H-reflex, a monitor of hyperreflexia, was recorded 4 weeks post-injury. Our results suggest that the activity-dependent increase in KCC2 functionally contributes to H-reflex recovery and critically depends on BDNF activity. This study provides a new perspective in understanding how exercise impacts hyperreflexia by identifying the biological basis of the recovery of function.
Capilla-Lopez J, Hernandez R, Carrero-Rojas G, Calvo P, Alvarez F, de la Cruz R Int J Mol Sci. 2024; 25(18).
PMID: 39337430 PMC: 11432591. DOI: 10.3390/ijms25189942.
Malloy D, Cote M Exp Neurol. 2024; 376:114754.
PMID: 38493983 PMC: 11519955. DOI: 10.1016/j.expneurol.2024.114754.
Kerzonkuf M, Verneuil J, Brocard C, Dingu N, Trouplin V, Ramirez Franco J Mol Ther. 2024; 32(4):1096-1109.
PMID: 38291756 PMC: 11163198. DOI: 10.1016/j.ymthe.2024.01.029.
Malloy D, Cote M bioRxiv. 2023; .
PMID: 37961233 PMC: 10634766. DOI: 10.1101/2023.10.24.563419.
Inhibitory Synaptic Influences on Developmental Motor Disorders.
Fogarty M Int J Mol Sci. 2023; 24(8).
PMID: 37108127 PMC: 10138861. DOI: 10.3390/ijms24086962.